

IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES

13 September 2021



DISCLAIMER

1. This presentation has been prepared by Neuren Pharmaceuticals Limited ARBN 111 496 130 (the Company or Neuren) in relation to the Company conducting:
 - a placement of fully paid ordinary shares (**New Shares**) to institutional and sophisticated investors under section 708A of the *Corporations Act 2001* (Cth) (**Corporations Act**) (**Placement**); and
 - an offer of New Shares to eligible shareholders in Australia and New Zealand under a share purchase plan in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**SPP** or **Share Purchase Plan**),
 (together, the **Placement** and the **SPP** are the **Offer**).

Summary information only

2. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Neuren, or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act. This presentation is to be read in conjunction with the most recent financial report and other periodic and continuous disclosure announcements lodged by the Company with the Australian Securities Exchange (**ASX**).
3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
4. Information in this presentation is current as at the date of this presentation (unless otherwise indicated) and remains subject to change without notice.

Not financial product advice

5. The Company does not warrant the accuracy, adequacy or reliability of the information in this presentation and, to the maximum extent permitted by law, disclaims all liability and responsibility flowing from the use of or reliance on such information by any person.
6. In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
7. An investment in securities is subject to known and unknown risks, some of which are beyond the control of the Company and its directors, including possible loss of income and capital invested.
8. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Investors should also have regard to the “Key Risks” section in this presentation when making their investment decision. Cooling off rights do not apply to the acquisition of New Shares.

Not a prospectus

9. This presentation is not a prospectus or disclosure document or product disclosure statement under Australian law (or under the law of any other jurisdiction in which an offer of New Shares may be received) and will not be lodged with the Australian Securities and Investments Commission.
10. This presentation may not be released to US wire services or distributed in the United States. It does not constitute an offer to issue or sell, or an invitation or recommendation to subscribe for, any securities in the United States. Any securities described in this presentation have not been, and will not be, registered under the US Securities Act of 1933 (**US Securities Act**) or the securities laws of any state or other jurisdiction in the United States, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The New Shares under the Offer will not be offered or sold, directly or indirectly, to any person in the United States.
11. The distribution of this presentation (including in electronic format) outside Australia may be restricted by law. Please see the section titled “Foreign Selling Restrictions” for more information.

DISCLAIMER (CONT'D)

Forward looking statements

12. This presentation contains forward looking statements about future events which reflect the Company's intent, belief and expectation as at the date of this presentation. As a result, forward looking statements involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, the Company can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs, competition or other general risks or factors.
13. Forward looking statements may include forecast financial and operating information about the Company, its strategies and statements about the industries and locations in which the Company operates. Forward looking statements can be identified by forward-looking terminology including, without limitation, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "due to" and other similar expressions within the meaning of securities laws of applicable jurisdictions.
14. There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. Forward looking statements are provided as a general guide only, are based on the information available to the Company as at the date of this presentation and should not be relied on as an indication, representation or guarantee of future performance.
15. You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic. Subject to any legal obligation to do so, the Company will not update or review any forward looking statements.

Past performance

16. Past performance (including past performance of the Company's share price) should not be relied upon as (and is not) an indication or guarantee of the Company's future performance. The historical information in this presentation is, or is based upon, information contained in previous announcements made by Neuren to the market, which are available at www.asx.com.au.

Other

17. By receiving this presentation and to the extent permitted by law, you agree to release the Company and its officers, employees, agents, associates, subsidiaries and advisers from any liability including, without limitation, any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
18. To the maximum extent permitted by law, the Company, its officers, employees, agents, associates, subsidiaries and advisers exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in or failure to participate in the Offer and the information in the presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Company, its officers, employees, agents, associates, subsidiaries and Advisers make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.
19. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.
20. You acknowledge and agree that determination of eligibility of investors for the purposes of the Placement and the SPP is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of the Company and the Lead Managers. The Company and the Lead Managers disclaim any duty or liability (including for negligence) in respect of the exercise or otherwise of that discretion, to the maximum extent permitted by law.

INVESTMENT HIGHLIGHTS

Neuren (ASX: NEU) is a biotechnology company developing new therapies in global markets for multiple serious neurological disorders that emerge in early childhood

1

Two patented drugs (trofinetide and NNZ-2591) administered as oral liquids

2

In Phase 3 and Phase 2 clinical development for 6 orphan drug indications, all with urgent unmet need

3

Near term inflection point with Phase 3 results for trofinetide due in Q4 2021

4

Trofinetide licensed to Acadia for North America, milestones up to US\$455m + double digit % royalties + data for rest of the world

5

Accelerating Phase 2 development of NNZ-2591 in 4 indications

6

NNZ-2591 novel mechanism of action has many more potential applications

CAPITAL RAISE FOR NEAR TERM CRYSTALLISATION OF VALUE

Raising ~A\$22m (via a A\$20m Placement and A\$2m Share Purchase Plan)

Neuren Today

~A\$250m market cap

- Trofinetide Rett syndrome Phase 3 results Q4 2021
- Existing US partner for trofinetide; significant interest from RoW
- NNZ-2591 Phase 2 for 3 indications
- Global rights to NNZ-2591 retained
- A\$16m cash at 31 July 2021

Post-raising

- Well capitalised to bring NNZ-2591 to Phase 3 in 4 indications
- Significant potential upside on successful trofinetide Phase 3 and US launch (US cashflow + RoW partnering)
- Proforma cash A\$37m¹

In 2023





- NNZ-2591 Phase 3 ready for 4 indications with potential markets 5 x Rett syndrome²
- Self-funded with trofinetide cash generated from US and RoW³
- Multiple value creation pathways through commercial arrangements and licensing globally

¹ Based on A\$16m cash at 31 July 2021 plus A\$21m raising proceeds assuming full subscription of the Offer and net of costs

² Based on number of addressable patients globally

³ Assuming positive results in Rett syndrome Phase 3 trial, New Drug Application (NDA) is approved by the FDA and product launch in United States

LEADING PIPELINE IN NEURODEVELOPMENTAL DISORDERS

Compound	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Commercial Partner	
Trofinetide	Rett syndrome ¹					<i>Results expected Q4 2021</i>	 (North America)
	Fragile X syndrome ¹						 (North America)
NNZ-2591	Phelan-McDermid syndrome ²			<i>Commence expected H2 2021</i>			
	Angelman syndrome ²			<i>Commence expected H2 2021</i>			
	Pitt Hopkins syndrome ²			<i>Commence expected H2 2021</i>			
	Prader-Willi syndrome ³			<i>Commence expected mid-2022</i>			

¹ Orphan Drug designation in US and EU, Fast Track designation in US

² Orphan Drug designation in US and EU ³ Orphan Drug designation in US


TREATING NEURODEVELOPMENTAL DISORDERS

Rett	Fragile X	Phelan-McDermid	Angelman	Pitt Hopkins	Prader-Willi
<i>MECP2</i>	<i>FMR1</i>	<i>SHANK3</i>	<i>UBE3A</i>	<i>TCF4</i>	<i>15q11-q13</i>



Impaired communication between neurons, abnormal formation/pruning of dendrites & chronic inflammation

Neuren's drugs target the critical role of IGF-1 in this upstream process, using analogs of peptides that can be taken orally as liquids



Severe impact on nearly every aspect of life		
walking and balance issues	anxiety and hyperactivity	seizures
speech impairment	intellectual disability	breathing irregularities
impaired hand use	sleep disturbance	gastrointestinal problems

COMMERCIAL ADVANTAGES OF ORPHAN DRUGS

Compared with existing markets that have apparently attractive large \$ sales revenue in which established products have to be displaced, **Orphan Drugs have many advantages**

Serious and urgent unmet need results in strong support from patient community and leading physicians as well as a more supportive regulatory environment

Ability to target a leadership position with little competition

Higher pricing

Evaluate Pharma Orphan Drug Report 2019 - US Orphan Drug mean cost of US\$150k per patient per year

Immediate access to known patients means large sales organisation less important

Exclusivity periods from regulators eliminate patent risk

Smaller and fewer Phase 3 trials

Statistics show higher probability of regulatory approval¹

~572k addressable patients across 6 indications²

¹ Biomedtracker/Amplion: Clinical Development Success Rates 2006-2015

² 96k in US, 122k in EU and 354k in Asia; estimates derived by applying the mid-point of the prevalence estimate range to the populations under 60 years

TRANSFORMING MILESTONES APPROACHING

- **Results in Q4 2021 for trofinetide Phase 3 trial in Rett syndrome**
 - Partnered with Acadia (NASDAQ:ACAD) for North America, Neuren has access to US data for ex-North America registration
 - Up to US\$455m milestone payments, plus double digit % royalties, plus one third of RPD Priority Review Voucher value¹
 - ACADIA funds development and commercialisation for North America
 - Neuren potential revenue over 2022 and 2023 for Rett syndrome in the US alone of A\$111 million plus double-digit percentage royalties on net sales²
 - Positive Phase 3 results expected to enable Neuren to partner in Europe and Asia

- **Phase 2 trials for NNZ-2591 in 4 disorders**
 - **Large potential upside** - multiple indications and global rights retained
 - Potential markets for NNZ-2591 is more than 5 times Rett syndrome³

¹ Refer to slide 19

² Refer to assumptions on slide 20

³ Based on estimates of number of addressable patients globally

THE THREE KEY DRIVERS OF NEAR TERM VALUE

Realise Neuren's share of trofinetide value in the US through ACADIA's Phase 3 results and New Drug Application

Implement commercial strategy for trofinetide ex-North America, using US data for registration

Confirm efficacy of NNZ-2591 in Phase 2 trials for 4 valuable indications

STRONG MOMENTUM FROM NEAR-TERM CATALYSTS

2021

Achieved

- ✓ EU Orphan designations for Phelan-McDermid, Angelman, and Pitt Hopkins
- ✓ Successful Phase 1 trial results for NNZ-2591
- ✓ Prader-Willi syndrome added to NNZ-2591 pipeline
- ✓ Complete drug substance manufacturing for NNZ-2591 Phase 2
- ✓ Pre-IND meetings with FDA to agree NNZ-2591 Phase 2 plans
- ✓ Acadia completes enrolment in trofinetide Rett syndrome Phase 3
- ✓ NNZ-2591 IND application for Angelman submitted to FDA
- ✓ **FDA Orphan designation for NNZ-2591 in Prader-Willi syndrome**

Imminent

- Submit NNZ-2591 IND applications for Pitt Hopkins and Phelan-McDermid to FDA
- Commence three NNZ-2591 Phase 2 trials
- Trofinetide Rett syndrome Phase 3 top-line results

2022

Expected

- Submit NNZ-2591 IND application for Prader-Willi to FDA
- Commence NNZ-2591 Phase 2 trial in Prader-Willi
- Trofinetide New Drug Application to FDA¹
- Trofinetide partnering in Europe and Asia¹
- Results from NNZ-2591 Phase 2 trials in each of Phelan-McDermid, Angelman and Pitt Hopkins

¹ Assuming positive results in Rett syndrome Phase 3 trial

PRADER-WILLI SYNDROME OVERVIEW

- ❑ Prader-Willi syndrome (PWS) is a debilitating neurodevelopmental disorder, caused by defects in the 15q11-q13 region of chromosome 15
- ❑ The estimated incidence is 1 in 10,000 – 30,000 males and females across all races and ethnicities (potentially 76k patients in US, EU, Asia¹)
- ❑ Infants with PWS have very low muscle tone and suffer from feeding difficulties
- ❑ An unregulated appetite and easy weight gain characterize the later stages of PWS, which can lead to morbid obesity
- ❑ A range of other problems can include intellectual and learning disabilities, growth hormone deficiency, sleep disturbances, speech difficulties, obsessive-compulsive symptoms, gastrointestinal complications, and difficulty controlling emotions
- ❑ Daily injection of growth hormone is the only medicine approved for PWS
- ❑ **PWS patients have sub-normal levels of IGF-1 - the mechanism of action of NNZ-2591 has the potential to address both endocrinological and neurological aspects of PWS**



¹ Refer to estimates on slide 25

FUNDING PRADER-WILLI AND PHASE 3 READINESS

Capital raise enables Neuren to accelerate NNZ-2591 to Phase 3 in 4 indications

- Pursue opportunity in Prader-Willi syndrome
 - FDA granted Orphan Drug designation on 2 September 2021
 - Compelling efficacy in *Magel2*-null mouse model - NNZ-2591 normalized fat mass, insulin levels, IGF-1 levels and all behavioural deficits¹
 - File IND application and commence Phase 2 trial in mid-2022, targeting results in 2023
- Complete the foundational work for Phase 3 trials across all indications
 - Non-clinical toxicology studies for chronic dosing in Phase 3 and commercial use
 - Manufacturing scale-up and commercial product presentation
 - Validation of efficacy measures

¹ Refer to results on slides 40-41

OFFER DETAILS

OFFER DETAILS

Neuren is conducting a capital raising of A\$22 million via an institutional placement and share purchase plan

<p>Offer Structure</p>	<ul style="list-style-type: none"> The Offer comprises: <ul style="list-style-type: none"> a placement of fully paid ordinary shares in the Company (“New Shares”) to institutional investors to raise approximately A\$20 million; and an offer of New Shares to eligible shareholders in Australia and New Zealand under a share purchase plan to raise approximately A\$2 million. The Offer is not underwritten
<p>Placement</p>	<ul style="list-style-type: none"> Placement to raise A\$20 million (“Placement”) <ul style="list-style-type: none"> Approximately 9.8m new Shares under the Company’s existing placement capacity under ASX Listing Rules 7.1/7.1A Represents ~8.5% of current issued capital
<p>Placement Pricing</p>	<ul style="list-style-type: none"> The offer price of A\$2.05 per share (“Offer Price”) represents: <ul style="list-style-type: none"> A discount of 8.9% to the last close of A\$2.25 on 9 September 2021 A discount of 12.7% to the 5-day VWAP of A\$2.347 up to and including 9 September 2021
<p>Share Purchase Plan</p>	<ul style="list-style-type: none"> Neuren intends to offer eligible shareholders an opportunity to subscribe for up to A\$30,000 of new Shares under a Share Purchase Plan (SPP) at a price per Share equal to the Offer Price It is intended the SPP will be capped at approximately A\$2 million
<p>Ranking</p>	<ul style="list-style-type: none"> New Shares issued under the Placement will rank pari passu with existing Shares from their date of issue

USE OF FUNDS

Uses	A\$m
IND application and Phase 2 clinical trial for NNZ-2591 in Prader-Willi syndrome	7.0
Foundational work for Phase 3 trials across all 4 indications for NNZ-2591	11.8
Working capital & Offer costs	3.2 ¹
Total	22.0

¹ Assuming full subscription of the Offer

OFFER TIMETABLE

Event	Date, AEST
Trading halt	Thursday, 9 September 2021
Record Date for SPP	Friday, 10 September 2021
Placement announced & Shares resume trading on ASX	Monday, 13 September 2021
Placement settlement of new Shares	Thursday, 16 September 2021
Placement issue of new Shares	Friday, 17 September 2021
SPP opens	Friday, 17 September 2021
SPP closes	Friday 1 October 2021
Issue of new Shares under SPP	Wednesday, 6 October 2021

The timetable is indicative only and subject to change by the Company and Lead Managers, subject to the Corporations Act and other applicable laws.

TROFINETIDE FOR RETT SYNDROME

TROFINETIDE LICENCE AGREEMENT WITH ACADIA

- Partnership commenced in August 2018, providing the necessary funding and capabilities to execute Phase 3 and commercialise trofinetide in the US
- Redacted agreement is available in ACADIA’s 2018 10K filing



Territory	North America (Neuren retains all rights ex-North America)
Indications	All, including Rett syndrome and Fragile X syndrome
Future development costs	Funded by ACADIA
Use of data	Each party has access to all data for use in its territory
Development Milestones	US\$105m on achievement of 5 milestones across Rett and Fragile X
Commercial Milestones	US\$350m on achievement of 4 thresholds for total annual net sales
Royalties	Double-digit % royalties with % escalating in 4 tiers of total annual net sales
Rare Pediatric Disease Priority Review Voucher	Neuren receives 1/3 of voucher market value (recent sale average US\$100m)
Non-compete	Neuren may not develop a competing product in indications for which ACADIA develops and commercialises trofinetide

RETT SYNDROME OPPORTUNITY

Estimates	US	Europe	Japan	China urban	Other Asia
Potential patients ¹	10,000	13,000	3,000	28,000	6,000
Patients currently identified	5,000	4,000	1,000	2,000	'00s


¹ Potential patient estimates derived by applying the mid-point of the published prevalence estimate range to the populations under 60 years

- ▣ Peak annual sales potential in US at least US\$500m²
- ▣ Neuren potential revenue over 2022 and 2023 for Rett syndrome in the US alone of A\$111 million³ plus double-digit percentage royalties on net sales
- ▣ Positive Phase 3 results expected to enable Neuren to partner in Europe and Asia
- ▣ Diagnosis rates expected to increase with awareness and accelerate with availability of a treatment

² Acadia 2Q18 Earnings Call presentation and Jefferies Healthcare Conference 2 June 2021

³ Assuming a New Drug Application (NDA) is approved by the FDA, the product is launched in the US, US\$33m is received as one third share of the value of a Rare Pediatric Disease Priority Review Voucher if awarded upon approval of a NDA, and a USD/AUD exchange rate of 0.75


RETT SYNDROME PHASE 3 PROGRAM




- ❑ LAVENDER™ enrolment completed – top-line results expected in Q4 2021
- ❑ 180 females aged 5 to 20 years
- ❑ RSBQ (caregiver) and CGI-I (physician) at 12 weeks are co-primary efficacy endpoints - both were positive in the Phase 2 trial
- ❑ Program includes DAFFODIL™ safety/PK trial in females aged 2 to 5 years
- ❑ Potential marketing approval in 2022 with Priority Review

RETT SYNDROME PHASE 2 - RSBQ AND CGI-I

Clinical improvement measured by RSBQ



Clinical improvement measured by CGI-I



RSBQ is a caregiver rating, reflecting the severity of the syndrome. Mean improvements for trofinetide and placebo were, respectively, 16% and 6%

CGI-I is a clinician rating of how much the subject's overall illness has improved or worsened. 22% of subjects on trofinetide received a score of 2 ("much improved") compared with 4% of subjects on placebo

RSBQ and CGI-I measure overall syndrome rather than a particular symptom, reflecting heterogeneity of symptoms and disease-modifying action of trofinetide

Publication: <https://n.neurology.org/content/early/2019/03/27/WNL.0000000000007316>

MAXIMISING PROBABILITY OF SUCCESS

- The Phase 3 co-primary endpoints were both positive in the Phase 2 trial
- In the Phase 2 trial clinical improvement continued increasing through to end of treatment - the Phase 3 trial at 12 weeks is twice the duration of the Phase 2 trial
- The Phase 3 sample size at approx. 90 per group is more than 3 times the Phase 2 sample size – much greater statistical power to detect a difference between active and placebo
- The dosing regimen in the active group for the Phase 3 trial is optimised, informed by the PK-PD analyses of the Phase 2 subjects
- The age range for the Phase 3 trial is 5 to 20 years, compared with 5 to 15 years in the Phase 2 trial
- Both trials are US sites only, with most Phase 2 sites participating in Phase 3

NNZ-2591 FOR MULTIPLE NEURODEVELOPMENTAL DISORDERS

ESTIMATES OF TARGET PATIENT POPULATIONS

Disorder	Gene mutation	Published prevalence estimates	Potential patients		
			US ¹	Europe ¹	Asia ^{1, 2}
Phelan-McDermid	<i>SHANK3</i>	1/8,000 to 1/15,000 males and females	22,000	28,000	81,000
Angelman	<i>UBE3A</i>	1/12,000 to 1/24,000 males and females	14,000	18,000	52,000
Pitt Hopkins	<i>TCF4</i>	1/34,000 to 1/41,000 males and females	7,000	9,000	25,000
Prader-Willi	<i>15q11-q13</i>	1/10,000 to 1/30,000 males and females	13,000	16,000	47,000
			56,000	71,000	205,000

- ▣ **Current opportunity for NNZ-2591 is more than 5 times the Rett Syndrome opportunity³**
- ▣ **There are many other neurodevelopmental disorders potentially relevant for NNZ-2591 mechanism of action**

¹ Estimates derived by applying the mid-point of the prevalence estimate range to the populations under 60 years


² Asia comprises Japan, Korea, Taiwan, Israel and urban populations of China and Russia

³ Based on number of addressable patients globally

NNZ-2591 MECHANISM OF ACTION

NNZ-2591 is a synthetic analog of cyclic glycine proline, a peptide that occurs naturally in the brain, designed to be more stable, orally bioavailable and readily cross the blood-brain barrier
NNZ-2591 can regulate the amount of IGF-1 that is available to activate IGF-1 receptors
 The effects of **NNZ-2591** are “state-dependent” – correcting impairment, but not impacting normal cells


NEURONS AND NEUROGLIAL CELLS



Produce essential growth factor

Activates PI3K–Akt–mTOR and Ras–MAPK–ERK signalling pathways in neurons, regulating formation of new synapses

IGF-1 receptor on cell surface



¹ doi: 10.1038/srep04388: Guan et al, 2017: Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1

FOUNDATIONS IN PLACE FOR MULTIPLE INDICATIONS

Neuren is leveraging experience from Rett syndrome program across all areas to execute much faster development for NNZ-2591

2022

Phase 2 data in multiple indications

2021

INDs approval by FDA

Commence Phase 2 trials in multiple indications

2020

Identify optimum dose

Develop and scale-up manufacturing

GMP manufacturing for Phase 2

Non-clinical safety studies

Phase 1 trial

3 EU Orphan designations

2019

Confirm blood brain barrier penetration

3 positive animal models

3 US Orphan designations

New patents in Europe and Japan

IDEAL ATTRIBUTES LEADING INTO PHASE 2

- ✓ Novel mechanism of action
- ✓ Clear and consistent efficacy in mouse models of each syndrome
- ✓ Biochemical effects in the brain and optimum dose confirmed
- ✓ Demonstrated high oral bioavailability and blood-brain barrier penetration
- ✓ IND-enabling program of non-clinical toxicology and CMC studies completed
- ✓ Proprietary drug substance manufacturing process with exceptional purity and high yield, administered as patient-friendly liquid dose
- ✓ Safe and well tolerated in Phase 1 trial
- ✓ Phase 2 plans confirmed at pre-IND meetings with FDA
- ✓ Orphan designations from FDA and EMA

THREE PHASE 2 TRIALS COMMENCING H2 2021

- ▣ Prioritising speed to data – results in H2 2022:
 - ▣ Angelman syndrome trial in Australia
 - ▣ Phelan-McDermid and Pitt Hopkins trials in US
 - ▣ Up to 20 patients in each trial
- ▣ First trials maximise opportunity to demonstrate effects:
 - ▣ Pediatric patients
 - ▣ 13 weeks' treatment
- ▣ Confirm safety and PK in pediatric patients
- ▣ Assess treatment impact across multiple efficacy measures

Overall aim – expedite data that enables subsequent trials to be designed as registration trials

PHASE 1 CLINICAL TRIAL HIGHLIGHTS

- ▣ Twice daily dosing for 7 days was safe and well tolerated at all dose levels tested in healthy volunteers
- ▣ No SAEs, no clinically significant findings in lab or cardiac tests
- ▣ All AEs mild or moderate and resolved during the trial
- ▣ At highest dose all AEs were mild apart from one moderate
- ▣ Most common AE was drowsiness

= Good safety and tolerability profile for dosing patients in Phase 2



APPENDIX

STOCK INFORMATION (ASX: NEU)

Current risk-adjusted valuation per share (MST Access) - A\$3.93

52 week price range: A\$1.00 - A\$2.53

Current share register composition before Offer (114 million quoted shares – top 20 hold 50%)



A\$16.0 million cash at 31 July 2021

MANAGEMENT AND BOARD

- Management team has devised and executed Neuren's Orphan Drug programs since 2013
- Extensive international pharmaceutical business experience
- Successfully developed drugs from pre-clinical through to FDA approval
- Executed multiple partnering transactions



Jon Pilcher
Chief Executive Officer



Larry Glass
Chief Science Officer



Dr Clive Blower
VP Product Development



Dr Nancy Jones
VP Clinical Development



James Shaw
VP Clin/Reg Operations



Patrick Davies
Non-exec Chairman



Dianne Angus
Non-exec Director



Dr Jenny Harry
Non-exec Director




Dr Trevor Scott
Non-exec Director



Lauren Frazer
CFO & Co. Secretary

CORRECTING IMPAIRED SIGNALING IN NEURONS


- ❑ Neurodevelopmental disorders result from different gene mutations, but all feature impaired signaling between neurons, with abnormal length and density of the dendritic spines that connect the neurons via synapses
- ❑ This impaired signaling causes behavioral, cognitive, motor and autonomic problems
- ❑ Trofinetide and NNZ-2591 address 3 characteristics common to these disorders:
 - Reduce inflammation associated with excessive inflammatory cytokines
 - Normalise abnormally low levels of IGF-1
 - Normalise the microglia phenotype for effective synaptic pruning and maintenance
- ❑ This restores the normal balance between protein synthesis forming new spines and maintenance of spines by microglia, correcting the length and density



Abnormal dendrites in *shank3* knockout mice

Normalisation after treatment with NNZ-2591


Correction of abnormal dendritic spines in mouse models:
 Left - Phelan-McDermid syndrome (*shank3*)
 Right - Fragile X syndrome (*fmr1*)



Correction in *fmr1* knockout mice after treatment with trofinetide (NNZ-2566)

CONSISTENT EFFICACY AND DOSE RESPONSE IN PHELAN-MCDERMID MODEL






PMS is caused by a deletion or other change in the 22q13 region of chromosome 22, which includes the *SHANK3* gene, or a mutation of the gene. In the *shank3* knockout mouse model, wild type mice and knockout mice were treated with placebo or 4 escalating dose levels of NNZ-2591 for 6 weeks. Results clearly indicate 2nd highest dose as optimum dose, informing dose selection for clinical trials in patients.



Incidence of seizures





WT + vehicle	KO + vehicle	KO + x mg/kg	KO + 2x mg/kg	KO + 4x mg/kg	KO + 8x mg/kg
0%	60%	50%	30%	10%	10%

CONSISTENT EFFICACY AND DOSE RESPONSE IN PHELAN-MCDERMID MODEL



BIOCHEMICAL EFFECTS CONFIRMED IN *SHANK3* MODEL

In biochemical testing, NNZ-2591 was shown to normalise the abnormal length of dendrite spines between brain cells, the excess activated ERK protein (pERK) and the depressed level of IGF-1 in *shank3* knockout mice.




Abnormal dendrites in *shank3* knockout mice

Normalisation after treatment with NNZ-2591


CONSISTENT EFFICACY IN ANGELMAN MODEL

AS is caused by a deletion or mutation in the ubiquitin protein ligase E3A (*UBE3A*) gene on chromosome 15. In the *ube3a* knockout mouse model, which resembles features of AS in humans, wild type and knockout mice were each treated with placebo or NNZ-2591 for 6 weeks. Treatment with NNZ-2591 normalized all the deficits in the knockout mice, **including eliminating seizures**, and had no effect on the wild type mice.




CONSISTENT EFFICACY IN PITT HOPKINS MODEL

PTHS is caused by the loss of one copy or a mutation of the *TCF4* gene on chromosome 18. In the *tcf4* mutation mouse model, which exhibits features of PTHS in humans, wild type mice and knockout mice were treated with placebo or NNZ-2591 for 6 weeks. Treatment with NNZ-2591 normalized all the deficits in the knockout mice and had no effect on the wild type mice.



CONSISTENT EFFICACY IN PRADER-WILLI MODEL


PWS is caused by mutations in the *15q11-q13* region of chromosome 15. In the *Magel2*-null mouse model, which exhibits features of PWS in humans, wild type mice and knockout mice were treated with placebo or NNZ-2591 for 6 weeks. Treatment with NNZ-2591 normalized fat mass, insulin levels, IGF-1 levels and all the behavioral deficits in the knockout mice and had no effect on the wild type mice.




Insulin levels (pM)					
WT plus vehicle	<i>Magel2</i> -null plus vehicle	WT plus NNZ-2591 low dose	<i>Magel2</i> -null plus NNZ-2591 low dose	WT plus NNZ-2591 high dose	<i>Magel2</i> -null plus NNZ-2591 high dose
110	173	112	143	115	119

CONSISTENT EFFICACY IN PRADER-WILLI MODEL


Hypoactivity (Open Field distance travelled)




Hypoactivity (Open Field time spent active)




Daily living (Nest building)




Social preference (novel mouse)



Social Interaction (Sniffing events)



Anxiety (Elevated Plus maze, time spent in open arm)



RISK FACTORS

RISK FACTORS

This section sets out some of the key risks associated with any investment in the Company, together with risks relating to participating in the Placement and SPP which may affect the value of the Company's securities.

The risks are not set out in order of importance and do not constitute an exhaustive list of all risks involved with an investment in the Company.

Before investing in the Company, you should carefully consider the risk factors and your personal circumstances. You should also consider all publicly available information, including the Company's ASX announcements available at www.asx.com.au.

Business Risk Factors

Reliance on key personnel

Due to the specialised nature of the Company's technology and products, its future depends on attracting and retaining suitably qualified senior management, scientific and research personnel.

The biotechnology industry has strong competition for highly skilled scientists and researchers due to the limited number of people with the appropriate skill set. The Company currently employs, or engages as consultants, a number of key senior management, scientific and research personnel.

There is a risk that the Company will be unable to attract and retain the necessary staff to pursue its strategies. This could materially and adversely affect the Company's business, operating results and financial prospects.

Contract risks generally

Neuren operates through a series of contractual relationships with licensors, sublicensees, independent contractors, distributors and suppliers. All contracts carry risks associated with the performance by the parties thereto of their obligations as to time and quality of work performed.

Risk as to technical capacity

The Company intends to carry out development work using appropriately chosen scientific research organisations. As such, it will be subject to the risk that staff in those organisations may have greater or lesser technical capacity than needed to achieve the results sought to be obtained from any development programme. No development programme is thus under the sole control of the Company. If, for any reason, incompetent staff in any such organisation carry out research then the results sought to be obtained may not be obtained or results apparently obtained may be inaccurate as a result of flawed research or development.

Development and commercialisation of the Company's intellectual property or products

The Company regards the content of certain of its technology as proprietary and relies primarily on a combination of copyright, patent and trade secrecy laws and employee and third party non-disclosure agreements to protect its rights. Those steps may, however, not be adequate to fully protect those rights. No assurances can be given that employees and/or third parties will not breach non-disclosure agreements or infringe or misappropriate the Company's rights.

Further, no assurance can be given that others will not challenge the ownership or validity of those proprietary rights by attacking either the Company or patent holders from whom the Company has acquired licences. In addition, effective copyright and patent protection may be unavailable or limited in certain countries.

Litigation may be necessary from time to time to enforce and protect the Company's rights. Such litigation can be costly and could have adverse effects on its activities, business, operating results and financial position. Likewise, a failure to succeed in protecting any such rights may equally have a materially adverse effect on the Company's activities, business, operating results and financial position.

It is possible that other parties may assert intellectual property infringement, unfair competition or like claims against the Company under copyright, trade secret, patent or other laws. While the Company is not aware of any claims of this nature in relation to any of the intellectual property rights in which it has interests, such claims, if made, may harm, directly and indirectly, the Company's business. If the Company is forced to defend against claims of intellectual property infringement, whether they are with or without merit or are determined in the Company's favour, the Company might face costly litigation and diversion of management's attention. As a result of such disputes, the Company may have to develop non-infringing technology or enter into royalty or licensing agreements. Such agreements, if necessary, may be unavailable on terms acceptable to the Company, or at all. If there is a successful claim of intellectual property infringement or unfair competition against the Company and it is unable to develop non-infringing technology or license the infringed or similar technology or content on a timely basis, it could harm the Company's business, operations and financial condition.

RISK FACTORS (CONT'D)

Competition

The Company's current and potential future competitors might include companies with significantly greater resources than Neuren. These competitors may develop products or services that are more effective and/or cheaper than those being developed by the Company, and as a consequence the Company's products or services may become uncompetitive, resulting in adverse effects on revenue, margins and profitability.

Product development

There are many risks inherent in the development of biotechnology products. They are subject to risks of failure during clinical trials or may fail to achieve sufficient robustness and reliability. The Company cannot guarantee that the development work being undertaken will result in the development of any products, or even if they do, that those products will be commercially successful.

Further, any material delays in the clinical trial process may substantially increase the cost of development. Material delays could also result in the Company failing to commercialise its products. Delays could occur during any stage of the development and commercialisation process including during toxicology studies, regulatory approval for late-stage clinical trials, manufacture of drug substance for late-stage clinical trials, enrolment of patients into clinical trials and/or scheduling delays by suppliers.

Sufficiency of funding

The Company has a business plan which will require a high level of expenditure until product revenue streams are established. In the future, Neuren may need to raise further financing through other public or private equity financings, collaborations or other arrangements with corporate or governmental sources, or other sources of financing to fund operations and achieve milestones. There can be no assurance that such additional financing, if available, can be obtained on terms reasonable to Neuren. In the event the Company is unable to raise additional capital, future operations may need to be curtailed or discontinued.

Product liability

Unforeseen problems, human error, deficiencies in research, development or testing or poor production quality of one or more of the Company's products may lead to product liability risk. In addition, as with all new products, there can be no assurance that unforeseen adverse events or defects will not arise. Adverse events may expose the Company to product liability claims or litigation, result in the loss of regulatory approvals for the relevant products and/or monetary damages being awarded against the Company.

While the Company currently has product liability insurance to cover these risks, there is no guarantee that the Company will be fully insured to cover its loss.

Regulatory risks

Operations by the Company may require approvals from regulatory authorities which may not be forthcoming or which may not be able to be obtained on terms acceptable to the Company. While the Company has no reason to believe that all requisite approvals will not be forthcoming, investors should be aware that the Company cannot guarantee that any requisite approvals will be obtained. A failure to obtain any approvals would mean that the ability of the Company to develop or operate any project may be limited or restricted either in part or absolutely.

Investment risk factors

Shareholder dilution

In the future, the Company may elect to issue Shares or engage in capital raisings to fund research and development or other activities, for working capital purposes or for other opportunities that the Company may decide to pursue. While the Company will be subject to the constraints of the Corporations Act, shareholders at the time may be diluted as a result of such issues of Shares and capital raisings.

Force majeure events

Events may occur within or outside Australia that could impact upon the Australian economy, the operations of the Company and the value of the Shares. The events include but are not limited to acts of terrorism, an outbreak of international hostilities, fires, floods, earthquakes, labour strikes, civil wars, natural disasters, outbreaks of disease (including COVID-19) or other natural or man-made events or occurrences that can have an adverse effect on the demand for the Company's products and its ability to conduct business.

RISK FACTORS (CONT'D)

Change in the Australian tax system

Any future changes in Australian tax law, including changes in interpretation or application of the law by the courts or taxation authorities in Australia, may affect the taxation treatment of the acquisition, holding and disposal of the New Shares and the market price of the New Shares.

Share market risks generally

Potential investors should recognise that the prices of shares fall as well as rise. Many factors affect the price of shares including local and international stock markets, movements in interest rates, economic and political conditions and investor and consumer sentiment.

New Shares risk

Investments in the New Shares are an investment in the Company and may be affected by the ongoing performance, financial position and solvency of the Company. The New Shares are not guaranteed by any government, government agency or compensation scheme in Australia or by any other person or any other jurisdiction.

Foreign currency risk

The underlying currency in which the Company's revenues and costs are denominated primarily in Australian dollars, US dollars and Sterling. The currency which the Company currently reports in is Australian dollars. The fact that the Company has a portion of its revenues and costs denominated in a currency other than its functional currency can and has created gains or losses arising from foreign exchange translations.

Political factors

Apart from exchange risks there are a wide range of other macroeconomic and political factors beyond the control of the Company which may affect the Company's operations including the consequences of terrorist and other activities which themselves impact adversely on the global economy and share market conditions and share prices generally.

Coronavirus (COVID-19)

Events related to the COVID-19 pandemic have resulted in significant market volatility. There is continued uncertainty as to ongoing and future response of governments and authorities globally as well as a likelihood of an Australian economic recession of unknown duration or severity. As such, the full impact of COVID-19 to consumer behaviour, suppliers, employees and the Company are not fully known. Given this, the impact of COVID-19 could potentially be materially adverse to the Company's financial and operational performance. Further, any government or industry measures may adversely affect the Company's operations and are likely beyond the control of Neuren. In compliance with its continuous disclosure obligations, the Company will continue to update the market in regard to any material impact of COVID-19 on its business.

Other

Other risk factors that apply generally in the conduct of a business, including litigation resulting from the breach of agreements or in relation to employees or contractors (through personal injuries, industrial matters or otherwise), loss of service of key management or operational personnel, non-insurable risks, delay in resumption of activities after reinstatement following the occurrence of an insurable risk and other matters that may all interfere with the Company's business and adversely affect its performance.

FOREIGN SELLING RESTRICTIONS

FOREIGN SELLING RESTRICTIONS

This presentation does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this presentation may not be distributed to any person, and the New Shares may not be offered or sold in any country outside of Australia, except to the extent permitted below.

New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act"). The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). No action has been taken in Hong Kong to authorise or register this document or to permit the distribution of this document or any documents issued in connection with it. Accordingly, the New Shares have not been and will not be offered or sold in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities. The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

United Kingdom

Neither this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended ("FSMA")) has been published or is intended to be published in respect of the New Shares.

The New Shares may not be offered or sold in the United Kingdom by means of this document or any other document, except in circumstances that do not require the publication of a prospectus under section 86(1) of the FSMA. This document is issued on a confidential basis in the United Kingdom to "qualified investors" within the meaning of Article 2(e) of the UK Prospectus Regulation. This document may not be distributed or reproduced, in whole or in part, nor may its contents be disclosed by recipients, to any other person in the United Kingdom. Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received in connection with the issue or sale of the New Shares has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of the FSMA does not apply to the Company.

In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 ("FPO"), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together "relevant persons"). The investment to which this document relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this document.